Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering

Core Viewpoint - Acurx Pharmaceuticals has announced a definitive agreement for the purchase and sale of 2,745,000 shares of its common stock at a price of $0.40 per share, along with a concurrent private placement of unregistered short-term warrants to purchase up to 8,235,000 shares of common stock [1][2] Group 1: Offering Details - The total gross proceeds from the offering are expected to be approximately $1.1 million before deducting fees and expenses [2] - The warrants will have an exercise price of $0.40 per share and will expire twenty-four months after stockholder approval [1] - The closing of the offering is anticipated to occur around March 10, 2025, subject to customary closing conditions [1] Group 2: Company Background - Acurx Pharmaceuticals is focused on developing a new class of small molecule antibiotics targeting difficult-to-treat bacterial infections [6] - The company's lead product candidate, ibezapolstat, is ready for Phase 3 trials for the treatment of C. difficile infection, with plans for international clinical trials this year [6] - The R&D pipeline includes antibiotic candidates targeting Gram-positive bacteria, including MRSA, VRE, and anthrax [6]